Detail akcie NuCana Sp ADR online

Business Summary: NuCana plc is a United Kingdom-based clinical-stage biopharmaceutical company. The Company is focused on developing treatment outcomes for patients with cancer by applying its ProTide technology. The Company's pipeline includes NUC-7738 and NUC-3373. NUC-7738 is an anti-cancer agent that disrupts Ribonucleic acid (RNA) polyadenylation, profoundly impacts gene expression in cancer cells and targets multiple aspects of the tumor microenvironment. NUC-7738 is in the Phase II part of a Phase I/II study which is evaluating NUC-7738 as a monotherapy in patients with advanced solid tumors and in combination with pembrolizumab in patients with melanoma. NUC-3373 is a chemical entity derived from the nucleoside analog 5-fluorouracil, a chemotherapy agent. NUC-3373 is being evaluated in a Phase Ib/II modular study (NuTide:303) of NUC-3373 in combination with the PD-1 inhibitor pembrolizumab for patients with advanced solid tumors and in combination with docetaxel for patients with lung cancer.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, NuCana PLC (ADR) revenues was not reported. Net loss increased 46% to L26.9M. Higher net loss reflects Administrative expenses increase of 57% to L7M (expense), Finance income decrease of 25% to L213K (income). Basic Earnings per Share excluding Extraordinary Items increased from -L65.15 to -L0.02.